SRCSGT | 65 | SOURCES SOUGHT NOTICE DADA09-05-T9001 FOR GABAPENTIN, Generic Codes: 000780, 100 mg; 000781, 300 mg; 000782, 400 mg IS REVISED TO EXTEND THE RESPONSE DATE.

FBO DAILY ISSUE OF APRIL 06, 2005 FBO #1227
SOURCES SOUGHT

65 -- SOURCES SOUGHT NOTICE DADA09-05-T9001 FOR GABAPENTIN, Generic Codes: 000780, 100 mg; 000781, 300 mg; 000782, 400 mg IS REVISED TO EXTEND THE RESPONSE DATE.

Notice Date: 4/4/2005
Notice Type: Sources Sought
Contracting Office: Great Plains Regional Contracting Ofc, ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200
ZIP Code: 78234-6200
Solicitation Number: DADA09-05-T9013
Response Due: 4/29/2005
Archive Date: 6/28/2005
Small Business Set-Aside: N/A
Description: Reference the Sources Sought Notice DADA09-05-T9001 issued DEC 22, 2004 to locate potential sources for the standardization of the pharmaceutical drug GABAPENTIN to secure best possible prices for the 45 Military Medical Treatment Facilities (MTFs) i n TRICARE Regions 6, 7, 8. The Response Date has been extended to 29 APRIL 2005. Products. GABAPENTIN: Generic code 000780, 100 mg has an estimated annual usage of 11,336 bottles (11,298 bottles in 100 tabs and 38 in 50 tabs). Generic code 000781, 300mg has estimated annual usage of 43,259 bottles (42,945 bottles in 100 tabs and 314 i n 50 tabs). Generic code 000782, 400mg has an estimated annual usage of 6,773 bottles (6,734 bottles in 100 tabs and 39 in 50 tabs). Criteria. Each vendor must not only meet all FDA requirements related to pharmaceuticals, medications, and vaccines but als o meet or demonstrate compliance with the base criterion for this product line. These criterion include but are not limited to the following: (1) Clinical studies demonstrating the safety and efficacy of the drug in appropriate populations. (2) Therapeutic advantages and disadvantages relative to accepted therapy. (3) Cost-effectiveness relative to accepted therapy. (4) Clinical support and education programs to each MTF. (5) Customer support in the form of a sales representative for each MTF within TRICARE Regions 6, 7& 8. (6) Unique NDC for each product. (7) Bar code labeling with NDC. (8) Existing FSS contract for each product and/or Distribution and Pricing Agreement (DAPA) for providing reliable distribution and consistent availability through our DoD P harmacy Prime Vendors (Reg 6- Bergen; Reg 7&8- Cardinal and Dakota Drug) for all TRICARE Region 6, 7&8 facilities. (9) Quarterly utilization data collection support to the Tri-Service Regional Business Office (TRBO). (10) A company returns policy. Selecti on. A Clinical Product Team (CPT) will evaluate this product line. CPTs are composed of healthcare providers who have expertise and knowledge of the products and will review products and literature submitted. TRICARE Regions 6, 7&8 deem the CPT members t o be medical experts. Therefore, they are qualified to determine and recommend which products are acceptable. The CPT recommendation can be based on literature review, presentation, demonstration, and physical or clinical evaluation. Recommendations by t he CPT will be at the sole discretion of the experts selected to review any offering. The drug(s) may or may not be listed on drug plan formularies, and recommendations may be deferred pending further information. Pricing. Regional Incentive Agreements (RIAs) can be exercised on the package size or bulk quantities deemed most advantageous to the Government. Price is the most important factor, and items may be awarded as an aggregate. Vendors are required to propose an incentive price in their submittal s for each line item listed to be considered for award. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have a unique NDC number. Offerors must provide bar code labeling which includes at a minimum t he NDC number. Additionally, offerors are encouraged to provide the expiration date and lot number in the bar code. Award will be made on the package size(s) most advantageous to the Government. The awardee(s) will be required to permit lower prices by the DoD Pharmaceutical Prime Vendor (PPV) up front. Any additional chargeback/rebate will be handled after the sale between the manufacturer and the appropriate DoD PPV. The chargeback/rebate process must be transparent to the MTF customer. The awardee( s) will permit the DoD PPV to load the lower discounted incentive price into their Electronic Order Entry System (EOES). The MTF customer shall see the lower incentive price on the DoD PPV EOES screen. Currently, neither Defense Medical Logistics Standar d Support (DMLSS), the Universal Data Repository (UDR) nor DSCP can loa d the regionally reduced prices. Under no circumstances shall the awardee attempt to charge the MTF customer the non-RIA price (i.e., the higher initial price) and attempt to provide the price difference via a chargeback/rebate after the sale. The awarde e(s) will assign a unique chargeback number to this Regional Incentive Agreement, to distinguish it from the original Government contract or other agreement price (i.e. FSS, DAPA, etc.). Contact Mr. Hill by email to obtain the pricing excel spreadsheet fo rmat to be used. Interested companies should provide Mr. Hill your company name, address, point of contact to address questions regarding your products, telephone, fax, answers to the listed criteria questions above, and pricing proposal(s) (excel spreads heet) no later than COB 29 APRIL 2005. Companies must also provide their FSS contract and/or DAPA number for their product(s). [For information regarding pharmaceutical DAPAs, contact DSCP, at (215) 737-7893.] Companies not responding by the suspense da te may be eliminated from consideration on any subsequent procurement action for these items. Again, all submittals must be received by COB 29 APRIL 2005. To participate, please contact Mr. Kevin Hill the Tri-Service Regional Business Office (TRBO), Bldg 3600, Room L34-1A, ATTN: SGLL-TRBO/Mr. Kevin Hill (210-916-7456), 3851 Roger Brooke Drive, San Antonio, TX 78234, e-mail: Kevin.Hill2@amedd.army.mil. Electronic communication is preferred.
Place of Performance: Address: Great Plains Regional Contracting Ofc ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive Fort Sam Houston TX; Zip Code: 78234-6200; Country: US
Record: SN00781453-W 20050406/050404212025 (fbodaily.com)
Source: FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's FBO Daily Index Page |

Loren Data's SAM Daily™

65 -- SOURCES SOUGHT NOTICE DADA09-05-T9001 FOR GABAPENTIN, Generic Codes: 000780, 100 mg; 000781, 300 mg; 000782, 400 mg IS REVISED TO EXTEND THE RESPONSE DATE.